Reuters logo
Sanofi discusses $275 per Actelion share for potential deal - Bloomberg
December 16, 2016 / 2:50 AM / in 10 months

Sanofi discusses $275 per Actelion share for potential deal - Bloomberg

(Reuters) - French drugmaker Sanofi (SASY.PA) is in advanced talks to buy Actelion Ltd (ATLN.S) and is discussing a price of about $275 per share for the Swiss drugmaker, Bloomberg reported on Thursday.

A long-time exposure shows the headquarters of Swiss biotech company Actelion in Allschwil, Switzerland December 6, 2016. Reuters / Arnd Wiegmann

The potential deal, which could come as soon as next week, would value Actelion at about $29.6 billion (23.86 billion pounds), Bloomberg reported, citing people with knowledge of the matter.

Actelion is in talks with Sanofi about a deal, Reuters reported on Wednesday, after U.S. healthcare group Johnson & Johnson (JNJ.N) abandoned efforts to buy the company.

Sanofi and Actelion could not immediately be reached for comment.

Reporting by Ismail Shakil in Bengaluru; Editing by Gopakumar Warrier

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below